Article thumbnail

Antineoplastic Effects of Gamma Linolenic Acid on Hepatocellular Carcinoma Cell Lines

By Shinji Itoh, Akinobu Taketomi, Norifumi Harimoto, Eiji Tsujita, Tatsuya Rikimaru, Ken Shirabe, Mitsuo Shimada and Yoshihiko Maehara


The aim of this study was to investigate the effect and the mechanism of gamma linolenic acid (GLA) treatment on human hepatocellular (HCC) cell lines. The human HCC cell line HuH7 was exposed to GLA. Cell proliferation and reactive oxygen species (ROS) generation including lipid peroxidation and apoptosis were compared. We then used a cDNA microarray analysis to investigate the molecular changes induced by GLA. GLA treatment significantly reduced cell proliferation, generated ROS, and induced apoptosis. After 24 h exposure of Huh7 cells to GLA, we identified several genes encoding the antioxidant proteins to be upregulated: heme oxygenase-1 (HO-1), aldo-keto reductase 1 family C1 (AKR1C1), C4 (AKR1C4), and thioredoxin (Trx). The HO-1 protein levels were overexpressed in Huh7 cells after GLA exposure using a Western blot analysis. Furthermore, chromium mesoporphyrin (CrMP), an inhibitor of HO activity, significantly potentiated GLA cytotoxicity. GLA treatment has induced cell growth inhibition, ROS generation including lipid peroxidation, and HO-1 production for antioxidant protection against oxidative stress caused by GLA in Huh7 cells. GLA treatment should be considered as a therapeutic modality in patients with advanced HCC

Topics: Original Article
Publisher: the Society for Free Radical Research Japan
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2000). A gene expression detabase for the molecular pharmacology of cancer.
  2. (2003). Activation of peroxisome proliferator activated receptor gamma by a novel synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest and apoptosis in breast cancer cells.
  3. (1996). An open-label phase I/II dose escalation study of the treatment of pancreatic cancer using lithium gamma linolenate.
  4. (1990). Anticancer activity of free gamma-linolenic acid on AH-109A rat hepatoma cells and the effect of serum albumin on anticancer activity of gammalinolenic acid in vitro.
  5. (1999). Arachidonic acid interaction with the mitochondrial electron transport chain promotes reactive oxygen species. Free Radic.
  6. (1987). Bilirubin is an antioxidant of possible physiological importance.
  7. (2000). Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway.
  8. (1998). Essential fatty acid: molecular and cellular basis of their anticancer action and clinical implications.
  9. (1997). Expression and characterization of recombinant type 2 3 alpha-hydroxysteroid dehydrogenase (HSD) from human prostate: demonstration of bifunctional 3 alpha/17 beta-HSD activity and cellular distribution.
  10. (1968). Formation of malonaldehyde from phospholipid arachidonate during microsomal lipid peroxidation.
  11. (2004). From bench to the clinic: gamma-linolenic acid therapy of human gliomas.
  12. (1998). Gamma linolenic acid (GLA) is cytotoxic to 36B10 malignant rat astrocytoma cells but not to ‘normal’ rat astrocytes.
  13. (2000). Gamma linolenic acid with tamoxifen as primary therapy in breast cancer.
  14. (2001). gamma-Linolenic acid and eicosapentaenoic acid induce modifications in mitochondrial metabolism, reactive oxygen species generation, lipid peroxidation and apoptosis in Walker 256 rat carcinosarcoma cells.
  15. (2007). Gamma-linolenic acid therapy of human glioma-a review of in vitro, in vivo, and clinical studies.
  16. (1967). Growth of cell-strains and primary cells on microcarriers in homogeneous culture.
  17. (1994). Heme oxygenase and oxidative stress. Evidence of involvement of bilirubin as physiological protector against oxidative damage.
  18. (1996). Heme oxygenase-1: function, regulation, and implication of a novel stress-inducible protein in oxidant-induced lung injury.
  19. (2000). Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones.
  20. (2004). Midkine protects hepatocellular carcinoma cells against TRAIL mediated apoptosis through downregulation of caspase-3 activity.
  21. (1997). Overexpression of Bcl-xL inhibits ara-c induced mitochondrial loss of cytochrome c and other perturbations that activate the molecular cascade of apoptosis.
  22. (1999). Overexpression of catalase in cytosolic or mitochondrial compartment protects HepG2 cells against oxidative injury.
  23. (2000). Oxidative stress and adenine nucleotide control of mitochondrial permeability transition. Free Radic.
  24. (2004). Role of expression of focal adhesion kinase in progression of hepatocellular carcinoma.
  25. (1993). Selection of metalloporphyrin heme oxygenase inhibitors based on potency and photoreactivity.
  26. (2004). Selenoprotein P, as a predictor for evaluating gemcitabine resistance in human pancreatic cancer cells.
  27. (2000). Systematic variation in gene expression patterns in human cancer cell lines.
  28. (2001). The reactive oxygen species—and Michael acceptorinducible human aldo-keto reductase AKR1C1 reduces the alpha,beta-unsaturated aldehyde 4-hydroxy-2-nonenal to 1,4-dihydroxy-2-nonene.
  29. (2002). The role of thioredoxin in protection against oxidative stress-induced apoptosis in SH-SY5Y cells.
  30. (2004). Thioredoxin reductase as a potential molecular target for anticancer agents that induce oxidative stress.
  31. (2000). Thioredoxin reductase.
  32. (1996). Vitamin E blocks the cytotoxic effect of γ-linolenic acid when administered as late as the time of onset of cell death— insight into the mechanism of fatty acid induced cytotoxicity.
  33. (2001). Vitamin E: protective role a Janus molecule.